Opicapone for Management of Sleep Disturbances in Parkinson’s Disease: Post-hoc Analysis of the OASIS trial in Patients With and Without Probable RBD

Ongentys (opicapone) - Ono Pharmaceutical, Neurocrine Biosciences, BIAL

https://onlinelibrary.wiley.com/doi/10.1111/ene.70629

J. Ferreira 1; M. Gago 2; R. Costa 3; M. Fonseca 4; H. Brigas 3; J. Holenz 3; C. Trenkwalder 5

Jun 12, 2026